These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 32026187)
1. Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders. Kaczorowski JA; Smith TF; Shrewsbury AM; Thomas LR; Knopik VS; Acosta MT Behav Genet; 2020 Jul; 50(4):191-202. PubMed ID: 32026187 [TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Shilyansky C; Lee YS; Silva AJ Annu Rev Neurosci; 2010; 33():221-43. PubMed ID: 20345245 [TBL] [Abstract][Full Text] [Related]
3. Neurodevelopmental disorders in children with neurofibromatosis type 1. Vogel AC; Gutmann DH; Morris SM Dev Med Child Neurol; 2017 Nov; 59(11):1112-1116. PubMed ID: 28845518 [TBL] [Abstract][Full Text] [Related]
4. Introduction to the Special Issue on 'The Genetic Architecture of Neurodevelopmental Disorders'. Taylor MJ; Polderman TJC Behav Genet; 2020 Jul; 50(4):185-190. PubMed ID: 32632490 [No Abstract] [Full Text] [Related]
5. Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms. Molosh AI; Shekhar A Prog Brain Res; 2018; 241():37-62. PubMed ID: 30447756 [TBL] [Abstract][Full Text] [Related]
6. Autism and attention-deficit/hyperactivity disorders and symptoms in children with neurofibromatosis type 1. Morotti H; Mastel S; Keller K; Barnard RA; Hall T; O'Roak BJ; Fombonne E Dev Med Child Neurol; 2021 Feb; 63(2):226-232. PubMed ID: 32406525 [TBL] [Abstract][Full Text] [Related]
7. An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains. Smith TF; Kaczorowski JA; Acosta MT Childs Nerv Syst; 2020 Oct; 36(10):2321-2332. PubMed ID: 32617712 [TBL] [Abstract][Full Text] [Related]
8. Brief Report: The Prevalence of Neurofibromatosis Type 1 among Children with Autism Spectrum Disorder Identified by the Autism and Developmental Disabilities Monitoring Network. Bilder DA; Bakian AV; Stevenson DA; Carbone PS; Cunniff C; Goodman AB; McMahon WM; Fisher NP; Viskochil D J Autism Dev Disord; 2016 Oct; 46(10):3369-76. PubMed ID: 27465244 [TBL] [Abstract][Full Text] [Related]
9. Language deficits in specific language impairment, attention deficit/hyperactivity disorder, and autism spectrum disorder: An analysis of polygenic risk. Nudel R; Christiani CAJ; Ohland J; Uddin MJ; Hemager N; Ellersgaard DV; Spang KS; Burton BK; Greve AN; Gantriis DL; Bybjerg-Grauholm J; Jepsen JRM; Thorup AAE; Mors O; Nordentoft M; Werge T Autism Res; 2020 Mar; 13(3):369-381. PubMed ID: 31577390 [TBL] [Abstract][Full Text] [Related]
10. Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials. Payne JM; Barton B; Shores EA; North KN J Neurol; 2013 Jan; 260(1):214-20. PubMed ID: 22875098 [TBL] [Abstract][Full Text] [Related]
11. The Potential Role of miRNAs as Predictive Biomarkers in Neurodevelopmental Disorders. Juvale IIA; Che Has AT J Mol Neurosci; 2021 Jul; 71(7):1338-1355. PubMed ID: 33774758 [TBL] [Abstract][Full Text] [Related]
12. Risk of Psychiatric and Neurodevelopmental Disorders Among Siblings of Probands With Autism Spectrum Disorders. Jokiranta-Olkoniemi E; Cheslack-Postava K; Sucksdorff D; Suominen A; Gyllenberg D; Chudal R; Leivonen S; Gissler M; Brown AS; Sourander A JAMA Psychiatry; 2016 Jun; 73(6):622-9. PubMed ID: 27145529 [TBL] [Abstract][Full Text] [Related]
13. The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Acosta MT; Bearden CE; Castellanos FX; Cutting L; Elgersma Y; Gioia G; Gutmann DH; Lee YS; Legius E; Muenke M; North K; Parada LF; Ratner N; Hunter-Schaedle K; Silva AJ Am J Med Genet A; 2012 Sep; 158A(9):2225-32. PubMed ID: 22821737 [TBL] [Abstract][Full Text] [Related]
15. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience. Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Rare Mutations in Autism: Elucidating Neurodevelopmental Mechanisms. Gamsiz ED; Sciarra LN; Maguire AM; Pescosolido MF; van Dyck LI; Morrow EM Neurotherapeutics; 2015 Jul; 12(3):553-71. PubMed ID: 26105128 [TBL] [Abstract][Full Text] [Related]
17. ADGRL3 rs6551665 as a Common Vulnerability Factor Underlying Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder. Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Müller D; Breda V; Teche SP; S Riesgo R; Schüler-Faccini L; Rohde LA; Grevet EH; Bau CHD Neuromolecular Med; 2019 Mar; 21(1):60-67. PubMed ID: 30652248 [TBL] [Abstract][Full Text] [Related]
18. Internalizing and neurodevelopmental problems in young people: Educational outcomes in a large population-based cohort of twins. Doering S; Lichtenstein P; Gillberg C; Kuja-Halkola R; Lundström S Psychiatry Res; 2021 Apr; 298():113794. PubMed ID: 33596506 [TBL] [Abstract][Full Text] [Related]
19. Loss of Dyson A; Ryan M; Garg S; Evans DG; Baines RA J Neurosci; 2022 Dec; 42(50):9450-9472. PubMed ID: 36344265 [TBL] [Abstract][Full Text] [Related]